Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma

Citation
J. Tammela et al., Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma, EUR J GYN O, 19(5), 1998, pp. 438-440
Citations number
21
Categorie Soggetti
Reproductive Medicine
Journal title
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
ISSN journal
03922936 → ACNP
Volume
19
Issue
5
Year of publication
1998
Pages
438 - 440
Database
ISI
SICI code
0392-2936(1998)19:5<438:CCCOTO>2.0.ZU;2-C
Abstract
Background: A review of literature comparing the survival of patients with clear cell carcinoma of the ovary to patients with serous carcinoma reveals divided opinions. No studies of statistical significance have demonstrated worse survival in a cohort of patients with clear cell carcinoma matched s tage for stage with patients with serous carcinoma of the ovary. The purpos e of this study was to compare survival in a cohort of clear cell carcinoma patients to a cohort of serous carcinoma patients matched for stage, age, treatment, and cytoreduction. Methods: All cases of clear cell carcinoma and serous carcinoma of the ovar y operated on by the gynecology oncology service from January 1, 1981 to De cember 31, 1989 were evaluated for patient age, length of survival and leve l of primary cytoreduction, as well as FIGO stage and histology. Results: Twenty-two patients with clear cell carcinoma found in the years n oted were compared to a cohort of 22 patients with serous carcinoma matched for stage (I, 18.2%; II, 9.1%; III, 63.6%; IV, 9.1%), age (clear cell carc inoma 58 years, serous carcinoma 60 years (p=0.330)), and level of primary cytoreduction (optimal in 63.6% of both clear cell carcinoma and serous car cinoma cohorts and non-optimal in 36.4% of both groups). Survival in the cl ear cell carcinoma cohort (16 months) was worse than in the serous carcinom a cohort (36 months) (p=0.045). Conclusion : Patients with clear cell carcinoma have a significantly worse prognosis than patients with serous carcinoma when matched for age, stage, and level of primary cytoreduction.